论文部分内容阅读
目的探索不同的DNA、重组痘苗病毒、蛋白疫苗免疫间隔在HIV-1疫苗prime-boost策略中对免疫效果的影响,为建立最佳免疫方案提供理论支持。方法对小鼠进行3针DNA初免,之后分别间隔3周、6周、12周、16周免疫重组痘苗病毒VTKgpe;对小鼠或兔子进行3针DNA初免,间隔16周免疫VTKgpe,之后分别间隔4周或8周免疫gp140蛋白。末次免疫后2周检测HIV-1特异性体液或细胞免疫应答。结果 DNA初免-VTKgpe加强间隔16周效果最佳,诱导的HIV-1 Env特异性抗体滴度达到105,分泌IFN-γ的T细胞数为5 966.4/106细胞。DNA初免,间隔16周VTKgpe加强,之后间隔4周或8周gp140蛋白加强效果差异无统计学意义。结论 DNA疫苗初免,16周后VTKgpe加强,4周后gp140蛋白加强可诱导较高的免疫应答,同时更为适宜临床试验及商业化应用的需要。
Objective To explore the effect of vaccinia vaccines and recombinant vaccinia virus vaccines on immunization in prime-boost strategy of HIV-1 vaccine and to provide theoretical support for the establishment of optimal immunization program. Methods Mice were immunized with 3-primed DNA and then immunized with recombinant vaccinia virus VTKgpe at 3, 6, 12 and 16 weeks respectively. The mice or rabbits were immunized with 3-primed DNA and immunized with VTKgpe at 16-week intervals. The gp140 protein was immunized at 4 weeks or 8 weeks apart. HIV-1-specific humoral or cellular immune responses were tested 2 weeks after the last immunization. RESULTS: DNA prime-VTKgpe was the best at 16-wk intervals, with an induced HIV-1 Env-specific antibody titer of 105 and IFN-γ-secreting T cells of 5 966.4 / 106 cells. DNA priming, VTKgpe enhanced at 16-week intervals, followed by 4 or 8 weeks after gp140 protein enhancement effect was not statistically different. Conclusions After DNA vaccine priming, VTKgpe is strengthened after 16 weeks. After 4 weeks, the enhancement of gp140 protein can induce a higher immune response and is more suitable for clinical trials and commercial application.